Affimed and NKMax America to Study the Combination of AFM24, an EGFR-Targeted Innate Cell Engager, with SNK01 Natural Killer Cell Therapy

Ads

You May Also Like

Celldex Reports Second Quarter 2017 Results

HAMPTON, N.J., Aug. 08, 2017 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported ...

Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer

VANCOUVER, British Columbia, Oct. 03, 2016 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals, Inc. (“Aquinox”) (NASDAQ:AQXP), ...

RedHill Biopharma Announces Collaboration With Germany’s Fraunhofer Institute for Oncology Drug RP101

TEL-AVIV, Israel, Feb. 08, 2016 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (TASE:RDHL) (“RedHill” ...